Phase 2a trial

Related by string. Phase 2a Trial * phase . phases . Phases . PHASE . PHASES : Phase III clinical trials . Phase III trials . Phase III clinical . Phase 2b clinical / 2As . 2AS . 2A : Class 2A Sectional . Evergreen 2A . H 2A . PIAA Class 2A / trialed . trialing . trials . Trial : Week Premium Trial . randomized controlled trial . randomized controlled trials . placebo controlled clinical trials * *

Related by context. All words. (Click for frequent words.) 82 Phase 2b trial 81 Phase 2b study 81 Phase IIa trial 80 Phase 2a clinical 80 Phase 2a 80 Phase 1b 80 phase IIa clinical 79 Phase Ib 78 Phase IIb trial 77 Phase Ib study 77 Phase 1b trial 77 phase IIb clinical 77 Phase IIb clinical 77 phase IIa 77 phase IIb 76 phase Ib 76 Phase Ib clinical 76 Phase 1b clinical 76 Phase IIa clinical 76 Phase IIb 76 Phase IIa 76 Phase IIb trials 76 Phase 2b clinical 76 dose escalation Phase 76 Phase 1a clinical 75 placebo controlled Phase 75 phase IIb trial 75 Phase III clinical 74 phase IIb study 74 Phase IIIb clinical 74 Phase Ia 73 multiple ascending dose 73 confirmatory Phase III 73 dose escalation trial 73 IIa trial 73 forodesine 73 Phase Ib II 73 phase 2a 73 Phase 2b 72 Phase #/#a 72 PRT# 72 INCB# [001] 72 ADVANCE PD 72 brivaracetam 72 alvespimycin 72 multicenter Phase 72 dose cohorts 72 multicenter Phase II 71 dose escalation clinical 71 registrational trial 71 pivotal Phase III 71 pharmacokinetic PK 71 Phase IIb clinical trials 71 Phase 1a 71 pharmacokinetic PK study 71 Phase III 71 GALNS 71 CR# vcMMAE 71 HGS ETR1 71 R#/MEM # 71 oral ridaforolimus 70 Phase #b/#a trial 70 huC# DM4 70 SUCCEED trial 70 ongoing Phase 1b 70 oral prodrug 70 phase Ib clinical 70 dose cohort 70 Phase IIB 70 Phase #b/#a 70 velafermin 70 PXD# 70 Phase 2b clinical trials 70 Amrubicin 70 registrational 70 Phase III trials 70 placebo controlled clinical 70 Phase III clinical trials 70 Phase IIa trials 70 APEX PD 70 elotuzumab 70 Phase 2a clinical trials 70 HGS# 70 ganetespib 70 dirucotide 70 riociguat 70 JAK inhibitor 70 HuMax EGFr 70 axitinib 70 RDEA# 69 pomalidomide 69 viral kinetic 69 NP2 Enkephalin 69 Traficet EN 69 PDE4 inhibitor 69 RSD# oral 69 dose escalation study 69 Phase III pivotal 69 PEG SN# 69 CIMZIA TM 69 BRIM2 69 clinical trial 69 randomized Phase III 69 IMA# 69 Phase 2b randomized 69 blinded randomized placebo controlled 69 rALLy clinical trial 69 INCB# [002] 69 HuMax CD4 69 Phase Ib clinical trials 69 Ophena TM 69 ADAGIO study 69 teriflunomide 69 PRX # 69 BAY #-# 69 Plicera 68 fosbretabulin 68 PRECiSE 68 confirmatory Phase 3 68 randomized controlled Phase 68 HuMax CD# 68 HCV SPRINT 68 PEG PAL 68 OncoVEX GM CSF 68 clinical pharmacology studies 68 IND submission 68 double blinded placebo 68 dose escalation 68 elacytarabine 68 PRTX 68 ILLUMINATE 68 randomized Phase IIb 68 evaluating tivozanib 68 budesonide foam 68 AEGR 68 Phase IIIb 68 single ascending dose 68 Phenoptin 68 lomitapide 68 bicifadine 68 CRLX# 68 AZILECT R 68 NO# [002] 68 OHR/AVR# 68 GAMMAGARD 68 Azedra 68 QLT# 68 lintuzumab 68 MAGE A3 ASCI 68 MEND CABG 68 virus HCV protease inhibitor 68 CIMZIA ™ 68 GLP toxicology studies 68 CCX# 68 Ozarelix 68 tanespimycin 68 CoFactor 68 cannabinor 68 XmAb# 67 ELACYT 67 lorvotuzumab mertansine 67 LUX Lung 67 ATL# [001] 67 vidofludimus 67 II Clinical Trial 67 Pimavanserin 67 Tarceva TM 67 Phase III placebo controlled 67 dosing cohort 67 Bezielle 67 teduglutide 67 pradefovir 67 ALN TTR# 67 Capesaris 67 BRIM3 67 Dextofisopam 67 enzastaurin 67 Phase #/#a trial 67 TMC# C# 67 PROMACTA 67 Tyrima 67 pivotal Phase 67 PSMA ADC 67 pivotal bioequivalence 67 tezampanel 67 Phase III randomized controlled 67 Phase III confirmatory 67 mertansine 67 HCV RESPOND 2 67 randomized Phase 67 orally bioavailable 67 PS# [001] 67 NGX# 67 maximally tolerated dose 67 eltrombopag 67 dosing cohorts 67 relapsed refractory multiple myeloma 67 Alzhemed TM 67 rNAPc2 67 MERLIN TIMI 67 AEG# 67 HQK 67 Fx #A 67 nucleotide analog 67 OvaRex ® MAb 67 pharmacodynamic PD 67 Triolex 67 Phase 2b Clinical Trial 67 TG# [003] 67 rilonacept 67 multicenter randomized placebo controlled 67 PANVAC VF 67 placebo controlled 67 pertuzumab 67 ataluren 67 midstage trials 67 PSN# [002] 67 Sym# 67 trodusquemine 67 PEG Interferon lambda 66 AQ4N 66 SNT MC# 66 crizotinib PF # 66 Carfilzomib 66 HCV protease inhibitor 66 ofatumumab 66 Phase III Clinical Trial 66 MEK inhibitor RDEA# 66 RG# [001] 66 ozarelix 66 pharmacokinetic studies 66 rALLy trial 66 visilizumab 66 Phase #b/#a clinical 66 ruxolitinib 66 ProSavin 66 SAR# [004] 66 Dacogen injection 66 Phase II 66 ascending dose 66 liposomal formulation 66 ISIS # 66 Nuvion 66 huN# DM1 66 Mipomersen 66 dacetuzumab 66 ocrelizumab 66 ENDEAVOR IV 66 CTAP# Capsules 66 fostamatinib 66 CA4P 66 KRN# 66 TMC# [002] 66 elagolix 66 adecatumumab 66 Zenvia Phase III 66 ZYBRESTAT 66 HCD# [002] 66 obatoclax 66 goserelin 66 YONDELIS 66 Phase IIa clinical trials 66 Apoptone 66 atacicept 66 metastatic hormone refractory 66 DermaVir Patch 66 preclinical studies 66 Phase IIIb study 66 randomized Phase 2b 66 ANCHOR trial 66 CHAMPION PCI 66 ularitide 66 docetaxel Taxotere R 66 HspE7 66 Pivotal Phase III 66 incyclinide 66 multicenter clinical 66 PHX# 66 MEK inhibitor 66 Corlux 66 glufosfamide 66 talactoferrin 66 APPRAISE 66 canakinumab 66 viral kinetics 66 phase IIIb 66 metaglidasen 66 celgosivir 66 selective androgen receptor modulator 66 initiate Phase IIb 66 IIa clinical trial 66 lumiliximab 66 neratinib 66 Cloretazine R VNP#M 66 EndoTAG TM -1 66 nonclinical studies 66 TOLAMBA 66 randomized placebo controlled 66 tolerability 65 Alocrest 65 deforolimus 65 Serdaxin 65 Randomized Phase 65 desvenlafaxine succinate 65 afatinib 65 safety tolerability 65 multicenter placebo controlled 65 refractory gout 65 multicenter Phase III 65 oral rivaroxaban 65 histone deacetylase HDAC inhibitor 65 ABSORB trial 65 PD LID 65 APTIVUS 65 MLN# 65 multicenter randomized Phase 65 GLYX 65 MGCD# [001] 65 Aurexis 65 zalutumumab 65 RGB # 65 efficacy endpoint 65 active comparator 65 Elocalcitol 65 bendamustine 65 placebo controlled Phase III 65 SCH # 65 oral methylnaltrexone 65 MYDICAR ® 65 HuLuc# 65 Bicifadine 65 NOX E# 65 tremelimumab 65 otelixizumab 65 IRX 2 65 investigational humanized monoclonal antibody 65 dexpramipexole 65 PNP inhibitor 65 SPIRIT FIRST 65 NVA# 65 systemic RNAi therapeutic 65 Phase 1b clinical trials 65 investigational compound 65 FOLOTYN ® 65 EOquin TM 65 CRMD# 65 mg/m2 cohort 65 Initiate Phase 65 IND enabling 65 Amigal 65 eprotirome 65 HGS ETR2 65 multicentre randomized 65 unblinding 65 Viramidine 65 reslizumab 65 Aplidin 65 Cimzia TM 65 preclinical efficacy 65 EchoCRT 65 octreotide implant 65 Zenvia ™ 65 ToGA 65 treatment naïve genotype 65 PROSTVAC TM 65 Omacetaxine 65 CEQ# 65 IIb clinical trial 65 TACI Ig 65 Cimzia ® certolizumab pegol 65 Ophena 65 eniluracil 65 torezolid phosphate 65 NLX P# 65 BCX# 65 non nucleoside inhibitor 65 urocortin 2 65 assessing T DM1 65 AeroLEF TM 65 immunomodulatory therapy 65 sunitinib malate 65 cetrorelix 65 INT# [002] 65 ZD# [001] 65 CBLC# 65 IMGN# 65 antibody MAb 65 Archexin 65 eosinophilic asthma 65 metastatic CRC 65 BLA submission 65 olaparib 65 LymphoStat B TM 65 Aurora kinase inhibitor 65 nitazoxanide 65 EVIZON 65 KNS # 65 pitavastatin 65 GOUT 65 pharmacodynamic profile 65 TRO# 65 ponatinib 65 initiate Phase 2b 65 ORMD 65 nalbuphine ER 65 RSD# 65 Locteron 65 mapatumumab 65 Phase 2b monotherapy 65 CCR5 antagonist 65 Ixempra 65 methylnaltrexone 65 Aflibercept 65 depsipeptide 65 preclinically 65 Phase III Clinical Trials 65 cobiprostone 65 tgAAC# 65 Chemophase 65 diabetic neuropathic pain 65 Laquinimod 65 Phase 1b dose escalation 65 EOquin 65 Xanafide 65 omega interferon 65 EDEMA3 65 stated Michelle Berrey 65 preclinical 65 trastuzumab emtansine T DM1 65 receptor tyrosine kinase inhibitor 65 AIR CF1 65 Reverset 65 TBC# 65 Cloretazine ® 65 prucalopride 64 iniparib 64 TELCYTA 64 velafermin belinostat 64 Ostarine 64 trabedersen 64 subcutaneous formulation 64 Phase IIb III 64 Maximum Tolerated Dose 64 Quinamed 64 regorafenib 64 anticancer compound 64 confirmatory clinical 64 Androxal TM 64 valopicitabine 64 amrubicin 64 RhuDex ® 64 PFO migraine 64 TPI ASM8 64 JAK1 64 ACTEMRA TM 64 SinuNase 64 AZILECT ® 64 CLARITY study 64 LymphoStat B 64 safety tolerability pharmacokinetics 64 cediranib 64 tesmilifene 64 Diamyd ® 64 Cethrin 64 Degarelix 64 Phase III ALLEGRO 64 GSK# [001] 64 PLX cells 64 Synavive 64 European Sepsis Trial 64 alvimopan 64 nab paclitaxel 64 recurrent glioma 64 plasma kallikrein inhibitor 64 COMFORT II 64 μg dose 64 glatiramer acetate 64 baminercept 64 Phase IIb Clinical Trial 64 randomized multicenter 64 eculizumab 64 ASSERT trial 64 investigational pan BCR 64 mGluR5 negative 64 dose escalation phase 64 TELINTRA 64 denufosol 64 treatment naive genotype 64 ENMD # 64 pharmacokinetics PK 64 trastuzumab DM1 64 protease inhibitor PI 64 Fibrillex TM 64 lead Aganocide compound 64 CORT # 64 dose dose escalation 64 MNTX 64 midstage clinical 64 Troxatyl 64 evaluable subjects 64 laquinimod 64 MAA submission 64 integrase inhibitor 64 novel histone deacetylase 64 IMC A# 64 PDX pralatrexate 64 investigational drug 64 thorough QT 64 interferon gamma 1b 64 Enzastaurin 64 trastuzumab DM1 T DM1 64 MGd 64 LibiGel ® 64 administered subcutaneously 64 DU #b 64 Valortim 64 ZYBRESTAT fosbretabulin 64 clinical trials 64 MBP# [001] 64 AP# [003] 64 safinamide 64 Altastaph 64 Pivotal Phase 64 double blinded randomized 64 ICA # 64 Veronate 64 rALLy 64 BLA filing 64 GFT# 64 Panzem R NCD 64 CB2 selective receptor agonist 64 Debio 64 ganaxolone 64 RLY# 64 REVIVE Diabetes 64 sitaxsentan 64 lintuzumab SGN 64 TLK# 64 initiate Phase 1b 64 cell lymphoma CTCL 64 mRCC 64 ADX# 64 lesinurad 64 Factor VIIa 64 Catena ® 64 GRN#L 64 pharmacodynamic effects 64 cariprazine 64 Panzem R 64 AZX# 64 intranasal formulation 64 dexanabinol 64 IMC #B 64 ALN TTR 64 ancrod 64 IIa clinical 64 oral deforolimus 64 PROVENGE sipuleucel T 64 refractory CLL 64 ALVESCO HFA 64 Pivotal Trial 64 Phase III Pivotal 64 Ocrelizumab 64 apremilast 64 polymerase inhibitor 64 inhibitor RG# 64 fidaxomicin Phase 3 64 Zerenex 64 PROPEL trial 64 alemtuzumab Campath 64 Dapagliflozin 64 relapsed MM 64 Pegasys plus Copegus 64 MEND CABG II 64 LEXIVA r 64 SinuNase TM 64 recurrent glioblastoma multiforme 64 DEB# 64 ANAVEX #-# [003] 64 farletuzumab 63 ORENCIA ® 63 HER2 positive metastatic breast 63 pegloticase 63 IDX# 63 PreCISe study 63 subcutaneously administered 63 IL# PE#QQR 63 RRMS patients 63 BrachySil TM 63 heavily pretreated 63 IMP# 63 LymphoStat B belimumab 63 rindopepimut 63 LibiGel Phase III 63 telaprevir VX 63 LY# [003] 63 rFIXFc 63 XL# [003] 63 RezularTM 63 Sapacitabine 63 romidepsin 63 ZOLINZA 63 opioid induced bowel dysfunction 63 relapsed multiple myeloma 63 AVADO 63 Cethromycin 63 tramiprosate Alzhemed TM 63 CLIRS trial 63 multicenter phase 63 tezampanel NGX# 63 JAK2 inhibitor 63 fluticasone furoate 63 Microplasmin 63 Exherin TM 63 #I TM# 63 orally administered inhibitor 63 refractory cutaneous T 63 Gabapentin GR 63 StemEx 63 DR Cysteamine 63 AEZS 63 Loramyc R 63 dextofisopam 63 randomized multicenter Phase III 63 ARRY 63 docetaxel chemotherapy 63 orBec 63 Personalized Immunotherapy 63 mTOR inhibitor 63 Triapine 63 metastatic HRPC 63 Genasense ® oblimersen 63 oral FTY# 63 Onalta ™ 63 sorafenib Nexavar 63 cilengitide 63 Phase 2b Trial 63 unblinded 63 MORAb 63 GLPG# 63 Menerba 63 Empatic 63 ThGRF 63 controlled multicenter 63 mGluR5 NAM 63 compound INCB# 63 Proxinium TM 63 GED aPC 63 darusentan 63 BRAF inhibitor 63 severe hypercholesterolemia 63 OMNARIS HFA 63 Diabetic Macular Edema 63 Virulizin ® 63 OMNARIS Nasal Spray 63 alagebrium 63 dextromethorphan quinidine 63 MIST II 63 pharmacodynamic 63 GRNVAC1 63 generation purine nucleoside 63 davunetide intranasal AL 63 LEUKINE 63 tolerability profile 63 OPT CHF 63 Aryplase 63 NXL# 63 squalamine 63 aflibercept 63 vicriviroc 63 atrasentan 63 CIMZIA TM certolizumab pegol 63 sapacitabine 63 Aclidinium 63 tocilizumab 63 Darusentan 63 Azilect ® 63 Phase IIb Trial 63 custirsen 63 dose limiting toxicities 63 AZOR 63 R# #mg BID 63 Prodarsan 63 Rezular 63 PROCHYMAL 63 EFAPROXYN 63 tolevamer 63 Vicriviroc 63 Nasulin 63 rapid virologic response 63 ritonavir boosted 63 Safinamide 63 AVN# [001] 63 Marqibo 63 Asentar 63 VNP#M 63 ARIKACE 63 voreloxin 63 mg kg dose 63 Spiegelmer ® 63 multicenter 63 iclaprim 63 temsirolimus 63 perifosine KRX 63 vascular disrupting agent 63 XL# SAR# 63 CytoFabTM 63 TriRima 63 Hsp# inhibitor 63 ONCONASE 63 TH# [003] 63 C1 INH 63 ascending doses 63 bortezomib Velcade 63 volociximab 63 TOCOSOL Paclitaxel 63 ARDIS 63 Annamycin 63 miconazole Lauriad ® 63 adipiplon 63 SYMMETRY trial 63 AIR CF2 63 PS# DARA 63 Dasatinib 63 ENRICH trial 63 GAMMAGARD LIQUID 63 Pharmacokinetics PK 63 placebo controlled randomized 63 HPTN 63 neurogenic orthostatic hypotension 63 Anturol TM 63 SPRYCEL ® 63 AMEVIVE 63 GAP #B# 63 palonosetron 63 Genz # 63 KRAS mutations occur 63 abiraterone acetate 63 ELND# 63 Vitaxin 63 subanalysis 63 TASKi2 63 pegylated interferon alpha 63 picoplatin 63 PEGylated interferon beta 1a 63 Plenaxis TM 63 zanolimumab 63 Nexavar sorafenib 63 Icatibant 63 TRIOLEX 63 decitabine 63 omacetaxine mepesuccinate 63 acyclovir Lauriad R 63 pharmacokinetic 63 PEGPH# 63 ribavirin RBV 63 inhaled formulation 63 PRE SURGE 63 Prosaptide 63 AGILECT R 63 multi kinase inhibitor 63 PEG IFN 63 anti leukemic 63 midstage studies 63 LCP AtorFen 63 dasatinib Sprycel ® 63 OXi# 63 ALN RSV# 63 pan HDAC inhibitor 63 Zoraxel 63 MabCampath 63 Phase 2a Clinical Trial 63 hormone refractory prostate cancer 63 senicapoc 63 novel VDA molecule 63 6R BH4 63 bevirimat Study 63 AIM HIGH 62 CCR5 mAb 62 ixabepilone 62 CD NP 62 LUMINATE 62 Phase Ib IIa 62 cangrelor 62 Dose escalation 62 LEVADEX 62 refractory AML 62 bardoxolone 62 investigational protease inhibitor 62 IPL# 62 metastatic castration resistant 62 Pivotal Study 62 dimebon 62 Phase IIA 62 mcg dose 62 tafamidis 62 lucinactant 62 VITAL Trial 62 phase IIb III 62 APTIVUS r 62 resminostat 62 tolerated dose MTD 62 Cleviprex TM clevidipine 62 Protexia ® 62 diarrhea predominant irritable 62 MDV# 62 ORACLE MS 62 adalimumab Humira 62 Cetrorelix 62 humanized anti 62 dirucotide MBP# 62 EDEMA3 trial 62 OMP #M# 62 Arikace 62 UPLYSO 62 TG MV 62 Cloretazine 62 Kahalalide F 62 vosaroxin 62 cutaneous T 62 solithromycin 62 OvaRex R 62 ZACTIMA 62 investigational monoclonal antibody 62 Firazyr 62 interferon beta 1b 62 perifosine 62 radezolid 62 daclizumab 62 CUSTOM III 62 DDP# 62 mg dose 62 personalized immunotherapy 62 BOLDER II 62 ATL/TV# 62 mipomersen 62 ApoB SNALP 62 PRECISE trial 62 CCR9 antagonist 62 standard chemotherapy regimen 62 HCV NS5B polymerase 62 Telatinib 62 talabostat 62 Phase III psoriasis 62 Allovectin 7 62 HyQ 62 OncoGel 62 low dose cytarabine 62 PRX# 62 sulodexide 62 Zybrestat 62 #mg QD [002] 62 posaconazole 62 prospective multicenter 62 Nanobody 62 Betaferon ® 62 APEX AMI trial 62 albinterferon alfa 2b 62 thymalfasin 62 ISTODAX 62 GRN# 62 GVAX 62 VA# [002] 62 REG2 62 statistically significant efficacy 62 multicenter randomized double 62 OncoVEX 62 monotherapy 62 Huntexil 62 Inhalation Solution 62 KB# [002] 62 proteasome inhibitor 62 adalimumab 62 ALN VSP 62 orally dosed 62 Allovectin 7 R 62 ACAPODENE 62 afamelanotide 62 targeted radiotherapeutic 62 Onrigin 62 label dose escalation 62 generation NNRTI 62 Hedgehog antagonist 62 generation antisense inhibitor 62 OMP #R# 62 maribavir 62 USL# 62 Symadex 62 sNDA submission 62 APOPTONE 62 CDK inhibitor 62 CLORETAZINE TM VNP#M 62 metreleptin 62 NEBIDO 62 evaluating Actimmune 62 preclinical toxicology 62 XL# XL# XL# XL# 62 CRx 62 SinuNase ™ 62 varespladib 62 angiogenesis inhibitor 62 Solazed 62 Atu# 62 Azedra TM 62 DSMB 62 trial evaluating PRX# 62 pharmacodynamics 62 NUVIGIL 62 placebo controlled clinical trials 62 CINQUIL 62 transcriptase inhibitor NNRTI 62 safety tolerability pharmacokinetic 62 ATACAND 62 Glufosfamide 62 oral formulation 62 Targretin 62 pharmacokinetic profile 62 Cotara 62 Enobia 62 Myocet 62 Tracleer R 62 Azixa 62 Stedivaze 62 BIM #A# 62 INCB# [003] 62 BLOOM DM 62 Civacir 62 pharmacokinetic PK profile 62 GW# [003] 62 ASA# 62 Phase 2a Study 62 EGS# 62 Aptivus ® 62 mCRC patients 62 PF # [002] 62 MT#/MEDI-# 62 Phase IIa proof 62 synthetic retinoid 62 DLTs 62 RAPAFLO 62 PKC# 62 DXL# 62 confirmatory Phase 62 TEMSO 62 samalizumab 62 aplindore 62 maturation inhibitor 62 T DM1 62 ASCEND HF 62 DASISION 62 CANCIDAS 62 Actilon 62 Memryte 62 Trofex 62 intravenous dosing 62 cathepsin K inhibitor 62 tipranavir 62 DB# [003] 62 Lu AA# 62 Neurodex 62 masked placebo controlled 62 Omigard 62 Clonicel 62 TG# [001] 62 MYDICAR 62 GetGoal Phase III 62 arzoxifene 62 phase III ACCLAIM 62 randomized clinical 62 ITAX 62 PLK1 SNALP 62 Tocosol Paclitaxel 62 MAXY G# 62 pazopanib 62 Study GL# 62 ruboxistaurin 62 OLpur TM H2H 62 NCCTG 62 MAP# 62 Clolar ® 62 Blinatumomab 62 ThermoDox R 62 ospemifene 62 Urocortin 2 62 odanacatib 62 vivo efficacy 62 midstage clinical trial 62 FTY# fingolimod 62 Tarvacin TM 62 BiTE R 62 HoFH 62 QNEXA 62 INC# 62 tasimelteon 62 Prodarsan ® 62 tasocitinib 62 TKM ApoB 62 enoximone 62 Gattex

Back to home page